A roadmap to improve the quality of atrial fibrillation management: Proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference

Europace

Volumn 18, Issue 1, 2015, Pages 37-50

  Kirchhof, Paulus ^a,b,c   Breithardt, Günter ^b,c   Bax, Jeroen ^d   Benninger, Gerlinde ^c   Blomstrom Lundqvist, Carina ^e   Boriani, Giuseppe ^f   Brandes, Axel ^g   Brown, Helen ^h   Brueckmann, Martina ^i,j   Calkins, Hugh ^k   Calvert, Melanie ^a   Christoffels, Vincent ^l   Crijns, Harry ^m   Dobrev, Dobromir ⁿ   Ellinor, Patrick ^o   Fabritz, Larissa ^a,b   Fetsch, Thomas ^p   Freedman, S Ben ^q   Gerth, Andrea ^c,r   Goette, Andreas ^c,s   Guasch, Eduard ^t   Hack, Guido ^u   Haegeli, Laurent ^v   Hatem, Stephane ^w   Haeusler, Karl Georg ^c,x   Heidbüchel, Hein ^y   Heinrich Nols, Jutta ⁱ   Hidden Lucet, Francoise ^z   Hindricks, Gerd ^aa   Juul Möller, Steen ^ab   Kääb, Stefan ^r,ac   Kappenberger, Lukas ^ad   Kespohl, Stefanie ^ae   Kotecha, Dipak ^a   Lane, Deirdre A ^a   Leute, Angelika ^c   Lewalter, Thorsten ^c,af   Meyer, Ralf ^ag   Mont, Lluis ^t   Münzel, Felix ^ah   Nabauer, Michael ^c,r   Nielsen, Jens C ^ai   Oeff, Michael ^c,aj   Oldgren, Jonas ^e,ak   Oto, Ali ^al   Piccini, Jonathan P ^am   Pilmeyer, Art ^an   Potpara, Tatjana ^ao   Ravens, Ursula ^c,ap   Reinecke, Holger ^b   Rostock, Thomas ^c,aq   Rustige, Joerg ^ab   Savelieva, Irene ^ar   Schnabel, Renate ^as   Schotten, Ulrich ^c,m   Schwichtenberg, Lars ^ae   Sinner, Moritz F ^r   Steinbeck, Gerhard ^c,at   Stoll, Monika ^au,av   Tavazzi, Luigi ^aw   Themistoclakis, Sakis ^ax   Tse, Hung Fat ^ay   Van Gelder, Isabelle C ^az   Vardas, Panagiotis E ^ba   Varpula, Timo ^bb   Vincent, Alphons ^ag   Werring, David ^bc   Willems, Stephan ^as   Ziegler, André ^bd   Lip, Gregory Y H ^a   Camm, A John ^ar   more..

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c Atrial Fibrillation Network (AFNET)   (Germany)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UPPSALA UNIVERSITY   (Sweden)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g ODENSE UNIVERSITY HOSPITAL   (Denmark)

^h Meda Pharma   (France)

ⁱ BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^j UNIVERSITY OF HEIDELBERG   (Germany)

^k JOHNS HOPKINS HOSPITAL   (United States)

^l UNIVERSITY OF AMSTERDAM   (Netherlands)

^m MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ UNIVERSITY OF DUISBURG ESSEN   (Germany)

^o HARVARD UNIVERSITY   (United States)

^p CRI The Clinical Research Institute   (Germany)

^q UNIVERSITY OF SYDNEY   (Australia)

^r UNIVERSITY OF MUNICH   (Germany)

^s St Vincenz Hospital   (Germany)

^t UNIVERSITY OF BARCELONA   (Spain)

^u BRISTOL MYERS SQUIBB   (United States)

^v UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^w Institute OfCardiometabolism and Nutrition   (France)

^x CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^y HASSELT UNIVERSITY   (Belgium)

^z PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^aa UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^ab Cardiome Pharma Corp   (Canada)

^ac DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^ad UNIVERSITY OF LAUSANNE   (Switzerland)

^ae BAYER PHARMA AG   (Germany)

^af Isar Heart Center   (Germany)

^ag Medtronic International Trading Sarl   (Switzerland)

^ah DAIICHI SANKYO CO   (Japan)

^ai AARHUS UNIVERSITY HOSPITAL   (Denmark)

^aj Klinikum Brandenburg   (Germany)

^ak UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

^al ANKARA NUMUNE HOSPITAL   (Turkey)

^am DUKE UNIVERSITY MEDICAL CENTER   (United States)

^an Boston Scientific   (United States)

^ao UNIVERSITY OF BELGRADE   (Serbia)

^ap DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^aq UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^ar ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^as UNIVERSITY HEART CENTER HAMBURG   (Germany)

^at Zentrum für Kardiologie und Angiologie am Klinikum Starnberg   (Germany)

^au UNIVERSITY OF MÜNSTER   (Germany)

^av MAASTRICHT UNIVERSITY   (Netherlands)

^aw Ettore Sansavini Health Science Foundation   (Italy)

^ax OSPEDALE DELL'ANGELO   (Italy)

^ay UNIVERSITY OF HONG KONG   (Hong Kong)

^az UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^ba UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^bb VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

^bc NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^bd Roche Diagnostics Ltd   (Switzerland)

more..

Author keywords

Antiarrhythmic drugs; Anticoagulation; Atrial fibrillation; Bleeding; Cardiovascular risk; Catheter ablation; Outcomes; Quality of care; Rate control; Research; Research priorities

Indexed keywords

ANTIARRHYTHMIC AGENT; BIOLOGICAL MARKER;

ABLATION THERAPY; ARTICLE; ATRIAL FIBRILLATION; CARDIAC PATIENT; CEREBROVASCULAR ACCIDENT; DISEASE CONTROL; ELECTROCARDIOGRAPHY; EVIDENCE BASED PRACTICE; GENETIC VARIABILITY; HEALTH CARE QUALITY; HEART RHYTHM; HUMAN; INFORMED CONSENT; MEDICAL DECISION MAKING; PATIENT CARE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RESEARCH PRIORITY; TOTAL QUALITY MANAGEMENT; TREATMENT OUTCOME; CARDIOLOGY; CLINICAL PATHWAY; CONSENSUS DEVELOPMENT; EUROPE; PRACTICE GUIDELINE; STANDARDS;

ATRIAL FIBRILLATION; CARDIOLOGY; CRITICAL PATHWAYS; EUROPE; HUMANS; PRACTICE GUIDELINES AS TOPIC; QUALITY IMPROVEMENT;

EID: 84949045129     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euv304     Document Type: Article

References (151)

1. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014; 129: 837-47
2. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-Analysis of randomised trials. Lancet 2014; 383: 955-62
3. Marijon E, Le Heuzey JY, Connolly S, Yang S, Pogue J, Brueckmann M, et al. Causes of death and influencing factors in patients with atrial fibrillation: a competing risk analysis from the randomized evaluation of long-Termanticoagulant therapy study. Circulation 2013; 128: 2192-201
4. Kirchhof P, Breithardt G, Camm AJ, Crijns HJ, Kuck KH, Vardas P, et al. Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial. Am Heart J 2013; 166: 442-8
5. Wilke T, Groth A, Mueller S, Pfannkuche M, Verheyen F, Linder R, et al. Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace 2013; 15: 486-93
6. Lip GY, Brechin CM, Lane DA. The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest 2012; 142: 1489-98
7. Kirchhof P, Breithardt G, Aliot E, Al Khatib S, Apostolakis S, Auricchio A, et al. Personalized management of atrial fibrillation: proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. Europace 2013; 15: 1540-56
8. Svennberg E, Engdahl J, Al-Khalili F, Friberg L, Frykman V, Rosenqvist M. Mass screening for untreated atrial fibrillation: the STROKESTOP Study. Circulation 2015; doi: 10.1161/CIRCULATIONAHA.114.014343
9. Grond M, Jauss M, Hamann G, Stark E, Veltkamp R, Nabavi D, et al. Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. Stroke 2013; 44: 3357-64
10. Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med 2014; 370: 2467-77
11. Hendriks JM, de Wit R, Crijns HJ, Vrijhoef HJ, Prins MH, Pisters R, et al. Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation. Eur Heart J 2012; doi: 10.1093/eurheartj/ehs071
12. Stewart S, Ball J, Horowitz JD, Marwick TH, Mahadevan G, Wong C, et al. Standard versus atrial fibrillation-specific management strategy (SAFETY) to reduce recurrent admission and prolong survival: pragmatic, multicentre, randomised controlled trial. Lancet 2015; 385: 775-84
13. Oldgren J, Healey JS, Ezekowitz M, Commerford P, Avezum A, Pais P, et al. Variations in cause and management of atrial fibrillation in a prospective registry of 15, 400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry. Circulation 2014; 129: 1568-76
14. Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE, et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol 2013; 61: 1998-2006
15. OECD. Health at a Glance: Europe 2014. Health Consumer Powerhouse, Euro Health Consumer Index. 2014 Report. 2014
16. Piccinocchi G, Laringe M, Guillaro B, Arpino G, Piccinocchi R, Nigro G, et al. Diagnosis and management of atrial fibrillation by primary care physicians in Italy: a retrospective, observational analysis. Clin Drug Investig 2012; 32: 771-7
17. Hendriks J, Tomini F, van Asselt T, Crijns H, Vrijhoef H. Cost-effectiveness of a specialized atrial fibrillation clinic vs. usual care in patients with atrial fibrillation. Europace 2013; 15: 1128-35
18. Dewland TA, Olgin JE, Vittinghoff E, Marcus GM. Incident atrial fibrillation among Asians, Hispanics, blacks, and whites. Circulation 2013; 128: 2470-7
19. Chang KC, Wang YC, Ko PY, Wu HP, Chen YW, Muo CH, et al. Increased risk of first-ever stroke in younger patients with atrial fibrillation not recommended for antithrombotic therapy by current guidelines: a population-based study in an East Asian cohort of 22 million people. Mayo Clin Proc 2014; 89: 1487-97
20. Siu CW, Lip GY, Lam KF, Tse HF. Risk of stroke and intracranial hemorrhage in 9727 Chinese with atrial fibrillation in Hong Kong. Heart Rhythm 2014; 11: 1401-8
21. Olesen JB, Sorensen R, Hansen ML, Lamberts M, Weeke P, Mikkelsen AP, et al. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011-2013. Europace 2015; 17: 187-93
22. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010; 12: 1360-420
23. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Europace 2012; 14: 1385-413
24. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, et al. 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64: 1-1
25. Excellence NIf C. Atrial fibrillation: Patient decision aid. 2014 2015
26. Potpara TS, Pison L, Larsen TB, Estner H, Madrid A, Blomström-Lundqvist C. How are patients with atrial fibrillation approached and informed about their risk profile and available therapies in Europe? Results of the European Heart Rhythm Association Survey. Europace 2015; 17: 468-72
27. Seaburg L, Hess EP, Coylewright M, Ting HH, McLeod CJ, Montori VM. Shared decision making in atrial fibrillation: where we are and where we should be going. Circulation 2014; 129: 704-10
28. Lane DA, Aguinaga L, Blomström-Lundqvist C, Boriani G, Dan GA, Hills MT, et al. Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardiáca y Electrofisiologiá (SOLEACE). Europace 2015; 17: 1747-69
29. US Department of Health and Human Services Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf (23 January 2015, date last accessed). December 2009
30. Basch E. New frontiers in patient-reported outcomes: adverse event reporting, comparative effectiveness, and quality assessment. Annu Rev Med 2014; 65: 307-17
31. Calvert M, Thwaites R, Kyte D, Devlin N. Putting patient-reported outcomes on the Big Data Road Map. J R Soc Med 2015; doi: 10.1177/0141076815579896
32. Anker SD, Agewall S, Borggrefe M, Calvert M, Jaime Caro J, Cowie MR, et al. The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials. Eur Heart J 2014; doi: 10.1093/eurheartj/ehu205
33. Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD, et al. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 2013; 309: 814-22
34. ISOQOL. Users guide to implementing patient-reported outcomes assessment in clinical practice. 2015 2015. http //www.isoqol.org/UserFiles/2015UsersGuide-Version2012.pdf (23 January 2015, date last accessed)
35. Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ, et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011; 123: 1501-8
36. Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF Cohort Study. J Am Coll Cardiol 2014; 64: 2222-31
37. Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA 2013; 310: 2050-60
38. de Vos CB, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG, Coelen RJ, et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol 2010; 55: 725-31
39. De Vos CB, Breithardt G, Camm AJ, Dorian P, Kowey PR, Le Heuzey JY, et al. Progression of atrial fibrillation in the REgistry on Cardiac rhythm disORDers assessing the control of atrial fibrillation cohort: clinical correlates and the effect of rhythm-control therapy. Am Heart J 2012; 163: 887-93
40. Friberg J, Buch P, Scharling H, Gadsbphioll N, Jensen GB. Rising rates of hospital admissions for atrial fibrillation. Epidemiology 2003; 14: 666-72
41. Friberg L, Rosenqvist M. Cardiovascular hospitalization as a surrogate endpoint for mortality in studies of atrial fibrillation: report from the Stockholm Cohort Study of Atrial Fibrillation. Europace 2011; 13: 626-33
42. National-Institute-for-Health-And-Care-Excellence. Atrial fibrillation: the management of atrial fibrillation. (Clinical guideline 180.) 2014. http: //guidance.nice.org.uk/CG180. 2014: http: //guidance.nice.org.uk/CG180 (June 2015, date last accessed)
43. Berti D, Hendriks JM, Brandes A, Deaton C, Crijns HJ, Camm AJ, et al. A proposal for interdisciplinary, nurse-coordinated atrial fibrillation expert programmes as a way to structure daily practice. Eur Heart J 2013; 34: 2725-30
44. Wynn GJ, Todd DM, Webber M, Bonnett L, McShane J, Kirchhof P, et al. The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. Europace 2014; 16: 965-72
45. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-72
46. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-100
47. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 2012; 14: 528-606
48. Lane DA, Barker RV, Lip GY. Best practice for atrial fibrillation patient education. Curr Pharm Des 2015; 21: 533-43
49. Hendriks JM, de Wit R, Vrijhoef HJ, Tieleman RG, Crijns HJ. An integrated chronic care program for patients with atrial fibrillation: study protocol and methodology for an ongoing prospective randomised controlled trial. Int J Nurs Stud 2010; 47: 1310-6
50. Clarkesmith DE, Pattison HM, Lip GY, Lane DA. Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial. PLoS ONE 2013; 8: e74037
51. Lane DA, Wood K. Cardiology patient page. Patient guide for taking the nonvitamin K antagonist oral anticoagulants for atrial fibrillation. Circulation 2015; 131: e412-5
52. Wynn GJ, Todd D, Webber M, Bonnett L, McSHane J, Kirchhof P, et al. The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. Europace 2014; 16: 965-72
53. Martinez C, Katholing A, Freedman SB. Adverse prognosis of incidentally detected ambulatory atrial fibrillation: a cohort study. Thromb Haemost 2014; 112: 276-86
54. Hobbs FDR, Fitzmaurice DA, Mant J, Murray E, Jowett S, Bryan S, et al. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over: the SAFE study. Health Technol Assess 2005; 9: iii-v, ix-x, 1-74
55. Lowres N, Neubeck L, Redfern J, Freedman SB. Screening to identify unknown atrial fibrillation. A systematic review. Thromb Haemost 2013; 110: 213-22
56. Wiesel J, Arbesfeld B, Schechter D. Comparison of the Microlife blood pressure monitor with the Omron blood pressure monitor for detecting atrial fibrillation. Am J Cardiol 2014; 114: 1046-8
57. McManus DD, Lee J, Maitas O, Esa N, Pidikiti R, Carlucci A, et al. A novel application for the detection of an irregular pulse using an iPhone 4S in patients with atrial fibrillation. Heart Rhythm 2013; 10: 315-9
58. Engdahl J, Andersson L, Mirskaya M, Rosenqvist M. Stepwise screening of atrial fibrillation in a 75-year-old population: implications for stroke prevention. Circulation 2013; 127: 930-7
59. Lowres N, Neubeck L, Salkeld G, Krass I, McLachlan AJ, Redfern J, et al. Feasibility and cost effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies: the SEARCH-AF study. Thromb Haemost 2014; 111: 1167-76
60. Tieleman RG, Plantinga Y, Rinkes D, Bartels GL, Posma JL, Cator R, et al. Validation and clinical use of a novel diagnostic device for screening of atrial fibrillation. Europace 2014; 16: 1291-5
61. Kaleschke G, Hoffmann B, Drewitz I, Steinbeck G, Naebauer M, Goette A, et al. Prospective, multicentre validation of a simple, patient-operated electrocardiographic system for the detection of arrhythmias and electrocardiographic changes. Europace 2009; 11: 1362-8
62. Aronsson M, Svennberg E, Rosenqvist M, Engdahl J, Al-Khalili F, Friberg L, et al. Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent ECG recording. Europace 2015; 17: 1023-9
63. Wilson JM, Jungner G. Principles and Practice of Screening for Disease. Geneva, Switzerland: World Health Organization
64. Leyden JM, Kleinig TJ, Newbury J, Castle S, Cranefield J, Anderson CS, et al. Adelaide stroke incidence study: declining stroke rates but many preventable cardioembolic strokes. Stroke 2013; 44: 1226-31
65. Hannon N, Sheehan O, Kelly L, Marnane M, Merwick A, Moore A, et al. Stroke associated with atrial fibrillation-incidence and early outcomes in the North Dublin population stroke study. Cerebrovasc Dis 2010; 29: 43-9
66. Friberg L, Rosenqvist M, Lindgren A, Terent A, Norrving B, Asplund K. High prevalence of atrial fibrillation among patients with ischemic stroke. Stroke 2014; 45: 2599-605
67. Sposato LA, Cipriano LE, Saposnik G, Vargas ER, Riccio PM, Hachinski V. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-Analysis. Lancet Neurol 2015; 14: 377-87
68. Kishore A, Vail A, Majid A, Dawson J, Lees KR, Tyrrell PJ, et al. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-Analysis. Stroke 2014; 45: 520-6
69. Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014; 370: 2478-86
70. Kamel H. Heart-rhythm monitoring for evaluation of cryptogenic stroke. N Engl J Med 2014; 370: 2532-3
71. Kirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey JY, Schilling RJ, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events European Registry in Atrial Fibrillation (PREFER in AF). Europace 2014; 16: 6-14
72. Lip GY, Laroche C, Ioachim PM, Rasmussen LH, Vitali-Serdoz L, Petrescu L, et al. Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year Follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). Eur Heart J 2014; doi: 10.1093/eurheartj/ehu374
73. Lip GY, Al-Khatib SM, Cosio FG, Banerjee A, Savelieva I, Ruskin J, et al Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches? J Am Heart Assoc 2014 3 doi: 10.1161/JAHA.114.001179
74. Nabauer M, Gerth A, Limbourg T, Schneider S, Oeff M, Kirchhof P, et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 2009; 11: 423-34
75. Kirchhof P, Nabauer M, Gerth A, Limbourg T, Lewalter T, Goette A, et al. Impact of the type of centre on management of AF patients: surprising evidence for differences in antithrombotic therapy decisions. Thromb Haemost 2011; 105: 1010-23
76. Gorst-Rasmussen A, Skjoth F, Larsen TB, Rasmussen LH, Lip GY, Lane DA. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. J Thromb Haemost 2015; doi: 10.1111/jth.12845
77. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, et al. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015; 131: 157-64
78. Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH, et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 2014; 16: 308-19
79. Le Heuzey JY, Ammentorp B, Darius H, De Caterina R, Schilling RJ, Schmitt J, et al. Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF Registry. Thromb Haemost 2014; 111: 833-41
80. Donze J, Clair C, Hug B, Rodondi N, Waeber G, Cornuz J, et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med 2012; 125: 773-8
81. Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999; 159: 677-85
82. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 975-83
83. Shore S, Carey EP, Turakhia MP, Jackevicius CA, Cunningham F, Pilote L, et al. Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. Am Heart J 2014; 167: 810-7
84. Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: considerations on once-vs. twice-daily regimens and their potential impact on medication adherence. Europace 2015; 17: 514-23
85. Ho CW, Ho MH, Chan PH, Hai JJ, Cheung E, Yeung CY, et al. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. Stroke 2015; 46: 23-30
86. Lip GY, Laroche C, Popescu MI, Rasmussen LH, Vitali-Serdoz L, Dan GA, et al. Improved outcomes with European Society of Cardiology guideline-Adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry. Europace 2015; 17: 1777-86
87. Gallego P, Roldan V, Marin F, Romera M, Valdes M, Vicente V, et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 2013; 110: 1189-98
88. Smith DE, Xuereb CB, Pattison HM, Lip GY, Lane DA. TRial of an Educational intervention on patients knowledge of Atrial fibrillation and anticoagulant therapy, INR control, and outcome of Treatment with warfarin (TREAT). BMC Cardiovasc Disord 2010; 10: 21
89. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110: 1087-107
90. Gallego P, Roldan V, Marin F, Galvez J, Valdes M, Vicente V, et al. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med 2014; 127: 1083-8
91. Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score. Chest 2013; 144: 1555-63
92. Heidbuchel H, Verhamme P, Alings M, Antz M, HackeW, Oldgren J, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625-51
93. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17: 1467-507
94. Stroke Unit Trialists Collaboration. Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev 2013; 9: CD000197
95. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010; 362: 1363-73
96. Camm AJ, Breithardt G, Crijns H, Dorian P, Kowey P, Le Heuzey JY, et al. Real-life observations of clinical outcomes with rhythm-And rate-control therapies for atrial fibrillation RECORDAF (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation). J Am Coll Cardiol 2011; 58: 493-501
97. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, et al. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individualpatient data meta-Analysis. Lancet 2014; 384: 2235-43
98. Kotecha D, Kirchhof P. Rate and rhythm control have comparable effects on mortality and stroke in atrial fibrillation but better data are needed. Evid Based Med 2014; 19: 222-3
99. Cosedis Nielsen J, Johannessen A, Raatikainen P, Hindricks G, Walfridsson H, Kongstad O, et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl J Med 2012; 367: 1587-95
100. Wilber DJ, Pappone C, Neuzil P, De Paola A, Marchlinski F, Natale A, et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA 2010; 303: 333-40
101. Arbelo E, Brugada J, Hindricks G, Maggioni AP, Tavazzi L, Vardas P, et al. The atrial fibrillation ablation pilot study: a European Survey on Methodology and results of catheter ablation for atrial fibrillation conducted by the European Heart Rhythm Association. Eur Heart J 2014; 35: 1466-78
102. Arbelo E, Brugada J, Hindricks G, Maggioni A, Tavazzi L, Vardas P, et al. ESCEURObservational Research Programme: the Atrial Fibrillation Ablation Pilot Study, conducted by the European Heart Rhythm Association. Europace 2012; 14: 1094-103
103. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 2010; 3: 32-8
104. Darkner S, Chen X, Hansen J, Pehrson S, Johannessen A, Nielsen JB, et al. Recurrence of arrhythmia following short-Term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). Eur Heart J 2014; 35: 3356-64
105. Kirchhof P, Andresen D, Bosch R, Borggrefe M, Meinertz T, Parade U, et al. Shortterm versus long-Term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet 2012; 380: 238-46
106. Kirchhof P, Sipido KR, Cowie MR, Eschenhagen T, Fox KA, Katus H, et al. The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology. Eur Heart J 2014; doi: 10.1093/eurheartj/ehu312
107. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev 2011; 91: 265-325
108. Wakili R, Voigt N, Kaab S, Dobrev D, Nattel S. Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest 2011; 121: 2955-68
109. Nattel S, Guasch E, Savelieva I, Cosio FG, Valverde I, Halperin JL, et al. Early management of atrial fibrillation to prevent cardiovascular complications. Eur Heart J 2014; doi: 10.1093/eurheartj/ehu028
110. Charitos EI, Purerfellner H, Glotzer TV, Ziegler PD. Clinical classifications of atrial fibrillation poorly reflect its temporal persistence: insights from 1, 195 patients continuously monitored with implantable devices. J Am Coll Cardiol 2014; 63: 2840-8
111. Plitt DC, Chung EH, Mounsey JP, Schwartz JD, Pursell IW, Gehi AK. Relation of atrial fibrillation burden and N-Terminal pro-brain natriuretic peptide. Am J Cardiol 2013; 111: 1315-8
112. Schnabel RB, Larson MG, Yamamoto JF, Sullivan LM, Pencina MJ, Meigs JB, et al. Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. Circulation 2010; 121: 200-7
113. Sinner MF, Stepas KA, Moser CB, Krijthe BP, Aspelund T, Sotoodehnia N, et al. B-Type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies. Europace 2014; 16: 1426-33
114. Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J, et al. NT-proBNP for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE trial. J Am Coll Cardiol 2013; doi: 10.1016/j.jacc.2012.11.082
115. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB Sr, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2935-59
116. Pena JM, MacFadyen J, Glynn RJ, Ridker PM. High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial. Eur Heart J 2012; 33: 531-7
117. Marott SC, Nordestgaard BG, Zacho J, Friberg J, Jensen GB, Tybjaerg-Hansen A, et al. Does elevated C-reactive protein increase atrial fibrillation risk? A Mendelian randomization of 47, 000 individuals from the general population. J Am Coll Cardiol 2010; 56: 789-95
118. Alonso A, Lopez FL, Matsushita K, Loehr LR, Agarwal SK, Chen LY, et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011; 123: 2946-53
119. Boriani G, Savelieva I, Dan GA, Deharo JC, Ferro C, Israel CW, et al. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-A position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace 2015; 17: 1169-96
120. Brugada R, Tapscott T, Czernuszewicz GZ, Marian AJ, Iglesias A, Mont L, et al. Identification of a genetic locus for familial atrial fibrillation. N Engl J Med 1997; 336: 905-11
121. Hodgson-Zingman DM, Karst ML, Zingman LV, Heublein DM, Darbar D, Herron KJ, et al. Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. N Engl J Med 2008; 359: 158-65
122. Parvez B, Vaglio J, Rowan S, Muhammad R, Kucera G, Stubblefield T, et al. Symptomatic response to antiarrhythmic drug therapy is modulated by a common single nucleotide polymorphism in atrial fibrillation. J Am Coll Cardiol 2012; 60: 539-45
123. Husser D, Adams V, Piorkowski C, Hindricks G, Bollmann A. Chromosome 4q25 variants and atrial fibrillation recurrence after catheter ablation. J Am Coll Cardiol 2010; 55: 747-53
124. Lubitz SA, Lunetta KL, Lin H, Arking DE, Trompet S, Li G, et al. Novel genetic markers associate with atrial fibrillation risk in Europeans and Japanese. J Am Coll Cardiol 2014; 63: 1200-10
125. Tada H, Shiffman D, Smith JG, Sjogren M, Lubitz SA, Ellinor PT, et al. Twelve-single nucleotide polymorphism genetic risk score identifies individuals at increased risk for future atrial fibrillation and stroke. Stroke 2014; 45: 2856-62
126. Everett BM, Cook NR, Conen D, Chasman DI, Ridker PM, Albert CM. Novel genetic markers improve measures of atrial fibrillation risk prediction. Eur Heart J 2013; 34: 2243-51
127. Wang J, Bai Y, Li N, Ye W, Zhang M, Greene SB, et al. Pitx2-microRNA pathway that delimits sinoatrial node development and inhibits predisposition to atrial fibrillation. Proc Natl Acad Sci USA 2014; doi: 10.1073/pnas.1405411111
128. Nattel S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol 2014; 63: 2335-45
129. McManus DD, Lin H, Tanriverdi K, Quercio M, Yin X, Larson MG, et al. Relations between circulating microRNAs and atrial fibrillation: data from the Framingham Offspring Study. Heart Rhythm 2014; 11: 663-9
130. Luo X, Pan Z, Shan H, Xiao J, Sun X, Wang N, et al. MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation. J Clin Invest 2013; 123: 1939-51
131. Dawson K, Wakili R, Ordog B, Clauss S, Chen Y, Iwasaki Y, et al. MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation. Circulation 2013; 127: 1466-75, 1475e1461-1428
132. Adam O, Lohfelm B, Thum T, Gupta SK, Puhl SL, Schafers HJ, et al. Role of miR-21 in the pathogenesis of atrial fibrosis. Basic Res Cardiol 2012; 107: 278
133. Sinner MF, Tucker NR, Lunetta KL, Ozaki K, Smith JG, Trompet S, et al. Integrating genetic, transcriptional, and functional analyses to identify 5 novel genes for atrial fibrillation. Circulation 2014; 130: 1225-35
134. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ 2015; 350: g7594
135. Kolek MJ, Parvez B, Muhammad R, Shoemaker MB, Blair MA, Stubblefield T, et al. A common variant on chromosome 4q25 is associated with prolonged PR interval in subjects with and without atrial fibrillation. Am J Cardiol 2014; 113: 309-13
136. Pfeufer A, van Noord C, Marciante KD, Arking DE, Larson MG, Smith AV, et al. Genome-wide association study of PR interval. Nat Genet 2010; 42: 153-9
137. Schnabel RB, Aspelund T, Li G, Sullivan LM, Suchy-Dicey A, Harris TB, et al. Validation of an atrial fibrillation risk algorithm in whites and African Americans. Arch Intern Med 2010; 170: 1909-17
138. Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D'Agostino RB Sr, et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet 2009; 373: 739-45
139. Cheng S, Keyes MJ, Larson MG, McCabe EL, Newton-Cheh C, Levy D, et al. Longterm outcomes in individuals with prolonged PR interval or first-degree atrioventricular block. JAMA 2009; 301: 2571-7
140. de Groot NM, Houben RP, Smeets JL, Boersma E, Schotten U, Schalij MJ, et al. Electropathological substrate of longstanding persistent atrial fibrillation in patients with structural heart disease. epicardial breakthrough. Circulation 2010; 122: 1674-82
141. Allessie MA, de Groot NM, Houben RP, Schotten U, Boersma E, Smeets JL, et al. Electropathological substrate of long-standing persistent atrial fibrillation in patients with structural heart disease: longitudinal dissociation. Circ Arrhythm Electrophysiol 2010; 3: 606-15
142. Eckstein J, Maesen B, Linz D, Zeemering S, van Hunnik A, Verheule S, et al. Time course and mechanisms of endo-epicardial electrical dissociation during atrial fibrillation in the goat. Cardiovasc Res 2011; 89: 816-24
143. Verheule S, Tuyls E, van Hunnik A, Kuiper M, Schotten U, Allessie M. Fibrillatory conduction in the atrial free walls of goats in persistent and permanent atrial fibrillation. Circ Arrhythm Electrophysiol 2010; 3: 590-9
144. Eckstein J, Verheule S, de Groot NM, Allessie M, Schotten U. Mechanisms of perpetuation of atrial fibrillation in chronically dilated atria. Prog Biophys Mol Biol 2008; 97: 435-51
145. Lankveld TA, Zeemering S, Crijns HJ, Schotten U. The ECG as a tool to determine atrial fibrillation complexity. Heart 2014; 100: 1077-84
146. Schotten U, Maesen B, Zeemering S. The need for standardization of time-And frequency-domain analysis of body surface electrocardiograms for assessment of the atrial fibrillation substrate. Europace 2012; 14: 1072-5
147. Platonov PG, Corino VD, Seifert M, Holmqvist F, Sornmo L. Atrial fibrillatory rate in the clinical context: natural course and prediction of intervention outcome. Europace 2014; 16 Suppl 4: iv110-19
148. Kuramatsu JB, Gerner ST, Schellinger PD, Glahn J, Endres M, Sobesky J, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 2015; 313: 824-36
149. Lewalter T, Kanagaratnam P, Schmidt B, Rosenqvist M, Nielsen-Kudsk JE, Ibrahim R, et al. Ischaemic stroke prevention in patients with atrial fibrillation and high bleeding risk: opportunities and challenges for percutaneous left atrial appendage occlusion. Europace 2014; 16: 626-30
150. Meier B, Blaauw Y, Khattab AA, Lewalter T, Sievert H, Tondo C, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. Europace 2014; 16: 1397-416
151. INVOLVE. Briefing notes for researchers: involving the public in NHS, public health and social care research. www.invo.org.uk/wp-content/uploads/2014/11/9938-INVOLVE-Briefing-notes-WEB.pdf ( (June 2015, date last accessed).